|
Measurable residual disease (MRD) represents a reliable marker to predict outcome and guide therapeutic decisions in acute lymphoblastic leukemia (ALL) management in both children and adults.
In Philadelphia-positive (Ph+) ALL, molecular MRD assessments rely on two markers, the oncogenic fusion BCR::ABL1 and the genomic clono-specific immunoglobulin and T-cell receptor (IG/TR).
Take the “I Can” pledge – a decision that improves patients’ lives – and join Dr. Rathana Kim as he reviews methodologies and clinical settings using both approaches in the modern therapy era.
|
